Compare UXIN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | IVVD |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 612.3M | 692.7M |
| IPO Year | 2018 | 2021 |
| Metric | UXIN | IVVD |
|---|---|---|
| Price | $2.86 | $2.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 83.2K | ★ 12.0M |
| Earning Date | 09-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $340,011,237.00 | $50,039,000.00 |
| Revenue This Year | $727.65 | $103.88 |
| Revenue Next Year | N/A | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 63.82 | ★ 332.71 |
| 52 Week Low | $2.45 | $0.35 |
| 52 Week High | $5.41 | $3.07 |
| Indicator | UXIN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 53.98 |
| Support Level | $2.56 | $2.09 |
| Resistance Level | $3.08 | $2.60 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 62.90 | 17.86 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.